Skip to main content

Table 2 The differences in clinical background between patients of the low dose group and the high dose group

From: The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients

  Low dosea < 0.2 mg/kg High dosea ≥ 0.2 mg/kg Univariate analysis
  n = 26 n = 21 p
Median(range) age at onset, years 36 (12–67) 31 (11–64) NS
Median(range) age at starting tacrolimus, years 42.5 (12–70) 36 (14–67) NS
Median(range) duration of disease, months 28.7 (0.74-336) 62.2 (0.97-323) NS
Gender    
Male/Female 10/16 14/7 0.08
Disease severity    
Moderate/Severe 20/6 14/7 NS
Extent of disease    
Pancolitis/Left-side colitis 19/7 15/ 6 NS
Medications    
5-ASA 25 17 0.16
Corticosteroid use 24 28 NS
Dose of corticosteroid at initiation of tacrolimus (PSL) 25 (0–40) 20 (0–30) 0.12
Immunomodulator use 8 5 NS
Bowel movement at initiation of tacrolimus (times/day) 8 (4–20) 7.5 (4–15) NS
Diet at initiation of tacrolimus    
Fasting 6 6 NS
Laboratory data at initiation of tacrolimus    
White blood cell count (×103/μL) 7.52 (4.71-15.0) 7.50 (5.46-15.2) NS
Hemoglobin (mg/dL) 11.2 (7.50-13.6) 10.4 (7.90-14.4) NS
Platelet count (×104/μL) 39.6 (9.70-65.6) 38.1 (12.0-75.2) NS
CRP (mg/dL) 0.93 (0.02-7.73) 2.20 (0.04-14.7) 0.053
SNPs analysisb    
CYP3A5 (*1*1/*1*3/*3*3) 0/2/19 1/10/5 0.001
ABCB1 exon26 (CC/CT/TT) 9/8/4 6/6/4 NS
  1. aPatients were divided into two groups by the maximum dose (<0.2 mg/kg or ≥ 0.2 mg/kg).
  2. bSNPs analyses were performed in 37 patients.
  3. SNPs, single-nucleotide polymorphisms.
  4. 5-ASA, 5-aminosalicylic acid.
  5. CRP, C-reactive protein.
  6. CYP3A5, cytochrome P450 3A4.
  7. ABCB1, ATP-binding cassette sub-family B member 1.